Key result
Purified EPA reduced CVD-attributable mortality compared to standard preventive therapy, with attenuated benefits seen for EPA/DHA.
Why the study?
Does purified EPA or mixed EPA/DHA reduce CVD-attributable mortality in patients undergoing primary or secondary prevention of cardiovascular disease?
Meta-Analysis (n=127,771)
Does purified EPA or mixed EPA/DHA reduce CVD-attributable mortality in patients undergoing primary or secondary prevention of cardiovascular disease?
Answers are grounded in this paper and cite their sources.
Purified EPA significantly reduces cardiovascular mortality compared to standard therapy in primary and secondary prevention, offering greater benefits than mixed EPA/DHA formulations.
BACKGROUND: Purified eicosapentaenoic acid (EPA) and mixed eicosapentaenoic/docosahexaenoic acids (EPA/DHA) are omega-3 polyunsaturated fatty acids (n-3 PUFAs) of interest for preventing cardiovascular disease (CVD) as adjunct to statins. Randomized clinical trial (RCT) evidence continues to emerge, including data from the RESPECT-EPA (Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid) trial, but n-3 PUFAs' roles in prevention remains controversial. OBJECTIVES: The objective of the study was to assess the efficacy of EPA vs EPA/DHA compared to the standard preventive therapy across published RCTs investigating the use of n-3 PUFAs for primary or secondary prevention of CVD. METHODS: Following a prespecified protocol registered in the PROSPERO database (CRD42023390587), we identified RCTs reporting CVD-attributable mortality in patients randomized to EPA, EPA/DHA, or a standard preventive therapy for primary or secondary CVD prevention. We used random effects meta-analysis to estimate pooled HRs of CVD-attributable mortality achieved with EPA or EPA/DHA relative to the standard preventive therapy. RESULTS: Sixteen RCTs met the inclusion criteria, representing 127,771 patients in total (41% women, mean age 64 ± 5 years). Median follow-up was 3.7 years (IQR: 2.7-5.0 years). Compared to the standard preventive therapy, CVD-attributable mortality was significantly reduced with purified EPA (HR: 0.79 [95% CI: 0.67-0.94]; P = 0.006); this effect was less for EPA/DHA (HR: 0.92 [95% CI: 0.84-1.00]; P = 0.044). CONCLUSIONS: EPA lowered incident CVD-attributable mortality in RCTs investigating its use for primary or secondary CVD prevention. Relative to EPA, benefits reported with EPA/DHA were attenuated. Although more work is needed to understand these differences, EPA should preferentially be used in cardiovascular conditions for which it is indicated.
No takes yet. Share an insight, caveat, or question.
Sheppard et al. (2025) conducted a meta-analysis in primary or secondary prevention of CVD (n=127,771). Purified eicosapentaenoic acid (EPA) vs. standard preventive therapy was evaluated on CVD-attributable mortality (HR 0.79, 95% CI 0.67-0.94, p=0.006). Purified EPA reduced CVD-attributable mortality compared to standard preventive therapy, with attenuated benefits seen for EPA/DHA.
Synapse has enriched 10 related papers. Consider them for comparative context: